- Report
- April 2025
- 175 Pages
Global
From €3979EUR$4,490USD£3,427GBP
- Report
- June 2025
- 400 Pages
Global
From €4386EUR$4,949USD£3,777GBP
- Report
- May 2024
- 129 Pages
Global
From €5759EUR$6,499USD£4,960GBP
- Report
- February 2024
- 110 Pages
Global
From €4209EUR$4,750USD£3,625GBP
- Report
- December 2022
- 217 Pages
Global
From €3190EUR$3,600USD£2,747GBP
- Report
- December 2022
- 79 Pages
North America
From €1329EUR$1,500USD£1,145GBP
- Report
- June 2024
- 112 Pages
Global
From €13288EUR$14,995USD£11,444GBP
Menopur is a brand of sexual and reproductive health drugs used to treat infertility in women. It is a gonadotropin-releasing hormone (GnRH) agonist, which works by stimulating the production of hormones that help to regulate the menstrual cycle and ovulation. Menopur is typically used in combination with other fertility treatments, such as in vitro fertilization (IVF). It is available in both injectable and oral forms.
Menopur is a popular choice for women seeking fertility treatments, as it is relatively safe and effective. It is also relatively affordable, making it accessible to a wide range of patients. Side effects of Menopur are generally mild and include headaches, nausea, and abdominal pain.
The Menopur market is highly competitive, with many companies offering similar products. Some of the major players in the market include Merck, Ferring Pharmaceuticals, Teva Pharmaceuticals, and Pfizer. Other companies include AbbVie, Sanofi, and Bayer. Show Less Read more